Search
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalIt is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine … N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.
Synonyms: N-Methyl nicotineamide, 3-(N-Methylcarbamoyl)pyridineFlortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS...
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalUnlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations.
Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineZuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalThis approval was based on favorable results from 2 phase 3 clinical trials.[L47691] … [A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression.
Amdinocillin
go.drugbank.com/drugs/DB01163ApprovedInvestigationalWithdrawnAmidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.
Dihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigational[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.
Alvimopan
go.drugbank.com/drugs/DB06274ApprovedInvestigationalAlvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.